209 related articles for article (PubMed ID: 29633253)
1. Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
Agostini A; Brunetti M; Davidson B; Göran Tropé C; Heim S; Panagopoulos I; Micci F
Int J Cancer; 2018 Sep; 143(6):1379-1387. PubMed ID: 29633253
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
4. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
5. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
6. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
7. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
8. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer update: lessons from morphology, molecules, and mice.
Cho KR
Arch Pathol Lab Med; 2009 Nov; 133(11):1775-81. PubMed ID: 19886711
[TBL] [Abstract][Full Text] [Related]
12. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
14. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas.
Gyftaki R; Liacos C; Politi E; Liontos M; Saltiki K; Papageorgiou T; Thomakos N; Haidopoulos D; Rodolakis A; Alevizaki M; Bamias A; Dimopoulos A
Int J Gynecol Cancer; 2014 Jun; 24(5):851-6. PubMed ID: 24844218
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.
Fridley BL; Dai J; Raghavan R; Li Q; Winham SJ; Hou X; Weroha SJ; Wang C; Kalli KR; Cunningham JM; Lawrenson K; Gayther SA; Goode EL
Cancer Epidemiol Biomarkers Prev; 2018 Sep; 27(9):1101-1109. PubMed ID: 29967001
[No Abstract] [Full Text] [Related]
16. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
17. Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival.
Yang JC; Risch E; Zhang M; Huang C; Huang H; Lu L
Future Oncol; 2017 Sep; 13(22):1981-1990. PubMed ID: 28829218
[TBL] [Abstract][Full Text] [Related]
18. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
[TBL] [Abstract][Full Text] [Related]
19. Low expression of miR-449 in gynecologic clear cell carcinoma.
Jang SG; Yoo CW; Park SY; Kang S; Kim HK
Int J Gynecol Cancer; 2014 Nov; 24(9):1558-63. PubMed ID: 25238166
[TBL] [Abstract][Full Text] [Related]
20. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
